- Home
- STFS vs VNRX Comparison
STFS vs VNRX Comparison
Compare STFS & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STFS
- VNRX
- Stock Information
- Founded
- STFS 2015
- VNRX N/A
- Country
- STFS China
- VNRX United States
- Employees
- STFS N/A
- VNRX N/A
- Industry
- STFS
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STFS
- VNRX Health Care
- Exchange
- STFS NYSE
- VNRX Nasdaq
- Market Cap
- STFS 71.7M
- VNRX 59.6M
- IPO Year
- STFS 2024
- VNRX N/A
- Fundamental
- Price
- STFS $14.80
- VNRX $0.63
- Analyst Decision
- STFS
- VNRX Strong Buy
- Analyst Count
- STFS 0
- VNRX 4
- Target Price
- STFS N/A
- VNRX $4.17
- AVG Volume (30 Days)
- STFS 887.5K
- VNRX 154.8K
- Earning Date
- STFS 02-14-2025
- VNRX 11-14-2024
- Dividend Yield
- STFS N/A
- VNRX N/A
- EPS Growth
- STFS 43.39
- VNRX N/A
- EPS
- STFS 0.15
- VNRX N/A
- Revenue
- STFS $14,972,726.00
- VNRX $1,285,827.00
- Revenue This Year
- STFS N/A
- VNRX $71,446.31
- Revenue Next Year
- STFS N/A
- VNRX N/A
- P/E Ratio
- STFS $95.95
- VNRX N/A
- Revenue Growth
- STFS 57.60
- VNRX 97.50
- 52 Week Low
- STFS $2.82
- VNRX $0.43
- 52 Week High
- STFS $17.91
- VNRX $1.23
- Technical
- Relative Strength Index (RSI)
- STFS N/A
- VNRX 48.89
- Support Level
- STFS N/A
- VNRX $0.61
- Resistance Level
- STFS N/A
- VNRX $0.65
- Average True Range (ATR)
- STFS 0.00
- VNRX 0.05
- MACD
- STFS 0.00
- VNRX 0.00
- Stochastic Oscillator
- STFS 0.00
- VNRX 38.10
About STFS STAR FASHION CULTURE HOLDINGS LIMITED
Star Fashion Culture Holdings Ltd is a content marketing solutions services provider. The company offer services focusing on marketing campaign planning and execution, offline advertising services; and online precision marketing services. The services also include marketing campaign planning and execution, events including marathons, sports events, and music festivals.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.